Overview

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of PD-L1/CTLA4 BsAb for the second line treatment and the combination with chemotherapy for the first line treatment in pancreatic cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Changhai Hospital
Treatments:
Albumin-Bound Paclitaxel
Calcium
Fluorouracil
Folfirinox
Folic Acid
Gemcitabine
Irinotecan
Oxaliplatin
Paclitaxel